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Targeted chemotherapyIn 1971, US President Nixon announced the “war on cancer”. This dec-
laration not only sparked global interest in this devastating disease but
also fuelled large investments. Interdisciplinary and international consor-
tia in academic and commercial cancer research and drug development
were fostered around the world. Some 40 years later, our understanding
of the cellular andmolecular pathophysiology ofmany cancer entities has
tremendously increased (Hanahan andWeinberg, 2011). This impressive
knowledge has led to the establishment of cancer prevention programs,
early diagnostics and more effective treatment strategies. However, de-
spite astonishing improvements in certain entities such as cervical,
-prostate, and breast cancer, the war on cancer has not been won
(Hanahan, 2014). In the US, a total of 1,658,370 new cancer cases and
589,430 cancer deaths are anticipated to occur in 2015 (Siegel et al.,
2015). Due to the growth and aging of the world population, cancer be-
comes a global economic problem. In Europe more than US$ 67 billion
are spent for cancer patients each year (Luengo-Fernandez et al., 2013).
Several treatment modalities have been developed and reﬁned for
cancer patients depending on the cancer type, stage, molecular and
histological subtype and other co-morbidities of the patient. Apart
from surgery, medical oncological treatment normally encompasses
chemotherapy, radiotherapy, targeted therapies, or a combination of
the aforementioned. Targeted therapies aim to disrupt certain signaling
pathways and epigenetic mechanisms that are dysregulated in cancerDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.04.011.
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and spread. Apart from remarkable exceptions (e.g. chronic myeloid
leukemia), many targeted therapies fail to achieve long-lasting remissions
and cancer cells become resistant to treatment over time. Chemo- and ra-
diotherapy target cancer cells less selectively by interfering with the repli-
cative cellularmachinery of highly proliferative cancer cells. Besides innate
and required resistance, one obvious disadvantage of this unselective cell
killing is the fact that healthy proliferating cells such as intestinal, hemato-
poietic- or hair follicle cells are also eliminatedby chemo-and radiotherapy
thus accounting for most of the acute side effects. Unfortunately, the
induction of DNA damage in living cells may also lead to carcinogenic
effects itself that only become overt several years after the termination of
chemo- and radiotherapy by the occurrence of secondary tumors.
Cisplatin [Pt(NH3)2Cl2] is a widely used platinum-based chemothera-
peutic agent that is used to treat a variety of cancers such as lung, cervical,
ovarian or head and neck cancers. The cytotoxicity of cisplatin has been
attributed to its ability to bind the cis-[Pt(NH3)2] unit to DNA. However,
cisplatin is also known as a radiosensitizing agent that augments the
DNA damaging effects of radiotherapy. Upon high energy radiation of
living cells, hydroxyl radicals (OH•) and free electrons with high kinetic
energy are generated. As electrons become hydrated (e−hyd) quickly,
OH• radicals have long been understood to be causative for DNA damage
upon irradiation. However, femtosecond (1 fs = 10−15) time-resolved
laser spectroscopy (fs-TRLS) has revealed a short lived prehydrated
state (e−pre) of free electrons that lasts less than a picosecond
(=10−12 s) before hydration occurs (Migus et al., 1987). Despite the
fact that e−pre has lost their kinetic energy, they form anions with nucle-
otides, predominantly dGMP− and dTMP−, that dissociate thus inducing
single- and double-strand breaks in DNA (Wang et al., 2009). This
reductive DNA damage mechanism was termed dissociative-electron-
transfer (DET) and was also shown for cisplatin where ultrashort-lived
e−pre form cis-Pt(NH3)2Cl• or cis-Pt(NH3)2• radicals leading to the forma-
tion of transient anions at cisplatin's binding site of DNA and subsequent
DNA damage (Lu et al., 2007). The discovery of thismechanismmay have
important implications for the design of novel anti-cancer therapies as
weakly bound electrons may be intrinsically abundant in cancer cells
thus sparing normal cells from DET induced DNA damage.
Indeed, in this issue of EBioMedicine, Lu et al. report thediscovery of a
new class of non-platinum-based compounds that comprise an aromat-
ic ring coupled to twoNH2 groups as the electron transfer promoter and
one or more halogen atoms (Lu et al., 2015). The absence of the heavy
metal platinum as coordinating ion results in a signiﬁcantly reduced
toxicity, while the novel so called femtomedicine (FMD) compoundsC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Using cervical, breast, ovarian and lung cancer cell lines and xenograft
tumors, the authors elegantly show signiﬁcant cytotoxicity of novel
FMD compounds against cancer cells in vitro and pronounced delay of
tumor growth in vivo. Mechanistically, FMD compounds led to DNA
damage, cell cycle arrest in the S-phase and programmed cell death.
Compared to cisplatin, non-platinum-based FMD compounds were less
efﬁcient to induce cell death in cancer cells but caused signiﬁcantly
less toxicity in normal skin and lung cells. This ﬁnding is remarkable as
the novel FMD compounds seem to exert certain selectivity for cancer
cells and essentially act as “targeted” chemotherapy. Previous data
have shown evidence that cancer cells may be characterized by a re-
duced intracellular environment and high levels of antioxidants with
weakly bound electrons. Indeed, the authors provide ﬁrst evidence
that treatment with FMD compounds selectively decreased the levels
of reduced glutathione (GSH) in cancer cells but increased in normal
cells. This data is consistent with the expected DET reaction between
FMD compounds and GSHmolecules and could explain the selective cy-
totoxic effect on cancer cells. Whether and to which extent antioxidants
and ROS contribute to tumor progression and therapeutic resistance is
still amatter of intense research (DeNicola et al., 2011). The observed ef-
fects may highly depend on the speciﬁc tissue and predisposing genetic
and metabolic alterations. Therefore, further investigations are needed
in this important ﬁeld to establish a causative relation between antioxi-
dant levels, ROS status and the amount of intrinsically available weakly
bound electrons in cancer cells. This knowledge could then be exploitednot only for novel therapeutic approaches but also for potential preven-
tive strategies.
In summary, the paper by Lu et al. presents a fascinating extension of
the armamentarium to ﬁght the war against cancer. However, further
preclinical evaluation of FMD compounds, preferably in genetically
engineered mice or patient-derived xenograft mice (avatars), is needed
to set the stage for early clinical trials in cancer patients.
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